Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Otsuka America Pharmaceutical |
---|---|
Information provided by: | NIH AIDS Clinical Trials Information Service |
ClinicalTrials.gov Identifier: | NCT00002337 |
To evaluate the safety and tolerability of four doses of oral vesnarinone in patients with advanced HIV disease.
Condition | Intervention | Phase |
---|---|---|
HIV Infections |
Drug: Vesnarinone |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Open Label, Safety Study |
Official Title: | A Phase I Safety and Tolerability Study of Four Doses of OPC-8212 (Vesnarinone) in Advanced HIV Disease |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria
Concurrent Medication:
Allowed:
Patients must have:
Exclusion Criteria
Co-existing Condition:
Patients with the following symptoms or conditions are excluded:
Concurrent Medication:
Excluded:
Concurrent Treatment:
Excluded:
Patients with the following prior conditions are excluded:
Prior Medication:
Excluded:
Prior Treatment:
Excluded within 30 days prior to study entry:
Study ID Numbers: | 234B, 22-93-252 |
Study First Received: | November 2, 1999 |
Last Updated: | June 23, 2005 |
ClinicalTrials.gov Identifier: | NCT00002337 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Acquired Immunodeficiency Syndrome Antiviral Agents vesnarinone |
Sexually Transmitted Diseases, Viral Immunologic Factors Acquired Immunodeficiency Syndrome Adjuvants, Immunologic Cardiovascular Agents Antiviral Agents Immunologic Deficiency Syndromes |
Virus Diseases Phosphodiesterase Inhibitors HIV Infections Sexually Transmitted Diseases Retroviridae Infections Vesnarinone |
Anti-Infective Agents Sexually Transmitted Diseases, Viral Slow Virus Diseases Molecular Mechanisms of Pharmacological Action Immunologic Factors Antineoplastic Agents Cardiotonic Agents Physiological Effects of Drugs Infection Therapeutic Uses Retroviridae Infections RNA Virus Infections Immune System Diseases Acquired Immunodeficiency Syndrome |
Adjuvants, Immunologic Enzyme Inhibitors Cardiovascular Agents Protective Agents Antiviral Agents Immunologic Deficiency Syndromes Pharmacologic Actions Virus Diseases Phosphodiesterase Inhibitors HIV Infections Sexually Transmitted Diseases Lentivirus Infections Vesnarinone |